Day: September 21, 2020

ALTAVISTA, Va., Sept. 21, 2020 (GLOBE NEWSWIRE) — Pinnacle Bankshares Corporation (OTCQX: PPBN) (“Pinnacle” or the “Company”), the holding company for First National Bank, today announced that it has completed a private placement of $8.0 million in fixed-to-floating rate subordinated notes due 2030 (the “Notes”). The Notes have been structured to qualify as Tier 2 capital under bank regulatory guidelines, and the proceeds from the sale of the Notes will be utilized to pay a portion of the cash consideration to be paid by the Company in connection with its pending merger with Virginia Bank Bankshares, Inc., if consummated, and to provide optionality for various growth opportunities and for general corporate purposes. In connection with the Notes offering, the Company was advised by Performance Trust Capital Partners, LLC as placement...

MONTREAL and BOCA RATON, Fla., Sept. 21, 2020 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today the approval of BIJUVA® (estradiol and progesterone) capsules by Health Canada. In Canada, BIJUVA is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in women with an intact uterus. VMS are commonly known as hot flashes or flushes and night sweats. VMS affect 60% to 80% of women entering menopause.1BIJUVA is a once-daily combination of estradiol and progesterone in a single oral capsule that will be available in two strengths in Canada. The two hormones included in BIJUVA have the same structure as the hormones produced and circulating in the woman’s body. In the U.S., BIJUVA is marketed by TherapeuticsMD...

MONTRÉAL et BOCA RATON, Fla., 21 sept. 2020 (GLOBE NEWSWIRE) — Thérapeutique Knight inc. (TSX : GUD) [« Knight »] et TherapeuticsMD, Inc. (NASDAQ : TXMD) [« TherapeuticsMD »], ont annoncé aujourd’hui l’approbation des gélules BIJUVA (estradiol et progestérone) par Santé Canada. Au Canada, BIJUVA est indiqué pour le traitement des symptômes vasomoteurs (SVM) modérés à sévères liés à la ménopause parmi les femmes dont l’utérus est intact. Les SVM sont couramment connus sous le nom de bouffées de chaleur et de sueurs nocturnes. Les SVM touchent de 60 à 80 % des femmes en début de ménopause.1BIJUVA est une combinaison d’œstradiol et de progestérone en une gélule orale pour administration uniquotidienne qui sera disponible en deux concentrations au Canada. Les deux hormones incluses dans BIJUVA présentent la même structure que les hormones...

NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) — Verizon Communications Inc. (“Verizon”) (NYSE, NASDAQ: VZ) today announced the commencement of two separate transactions to exchange certain series of its outstanding notes.The Exchange OffersThe first transaction consists of private offers to exchange the 7 outstanding series of notes listed in the first table below and maturing from 2021 through 2024 (collectively, the “Short-Dated Old Notes”), in each case, for newly issued notes of Verizon due 2030 (the “2030 New Notes”) (the “Short-Dated Exchange Offers”), on the terms and subject to the conditions set forth in an offering memorandum dated September 21, 2020 (the “Short-Dated Offering Memorandum”), and the second transaction consists of private offers to exchange the 10 outstanding series of notes listed in the second table below...

DERIDDER, La., Sept. 21, 2020 (GLOBE NEWSWIRE) — AMERISAFE, Inc. (Nasdaq: AMSF), a specialty provider of workers’ compensation insurance focused on high hazard industries, today announced it will release its 2020 third quarter financial results on Wednesday, October 28, 2020 after the market closes. In conjunction with the release, the Company has scheduled a conference call which will be broadcast live over the Internet on Thursday, October 29, 2020 at 10:30AM Eastern time.An archive of the webcast will be available after the call for a period of 60 days in the “Investors” section of the Company’s website.About AMERISAFEAMERISAFE, Inc. is a specialty provider of workers’ compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, manufacturing,...

DAYTONA BEACH, Fla., Sept. 21, 2020 (GLOBE NEWSWIRE) — Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company”) announced the acquisition of a portfolio of three single-tenant net-leased retail income properties located in Maine and leased to an affiliate of Dollar General. The leases are guaranteed by the investment grade-rated Dollar General parent entity. The portfolio was purchased for approximately $4.6 million, representing a going-in cap rate of 6.85%. Each of the leases with Dollar General has approximately 13.1 years remaining on its initial lease term. The Company funded the acquisition with the Company’s line of credit. Dollar General is now the Company’s fifth largest tenant as a percentage of annualized base rent.Including this newly acquired portfolio, the Company’s total portfolio now consists of 43 properties...

MILLERSBURG, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) — Mid Penn Bancorp, Inc. (“Mid Penn”) (NASDAQ: MBP), the parent company of Mid Penn Bank (the “Bank”) has announced the planned consolidation of three branches in the Bank’s retail network effective December 31, 2020. The consolidation, which affects its Malvern (Chester county), Pillow (Dauphin county), and Vanderbilt (Fayette county) locations, is part of Mid Penn’s strategy to optimize the delivery of banking services and in response to shifting consumer preferences.   Customers will continue to have access to nearby branches as well as a robust set of technology-based services.“As we prepare for new days ahead in our industry, we are continually evaluating how we deliver our brand of community banking to the customers and communities we serve. We are committed to providing easy...

TRYbeCA-1 Phase 3 trial in second-line metastatic pancreatic cancer:More than 90% of the planned 500 patients enrolledFast-Track designation granted by U.S. FDAInterim superiority analysis expected in Q1 2021; final analysis in 2H of 2021NOPHO-sponsored Phase 2 trial in second-line acute lymphoblastic leukemia:Completed patient enrollment: 55 patients enrolledEncouraging interim results: target level and duration of asparaginase activity reachedFinal data expected by the end of 2020Cash and cash equivalents of €45.4 million ($51.0 million) at the end of June 2020Cash horizon extended with a convertible bond financingEstablishment of At-The-Market (ATM) financing facility announcedLYON, France and CAMBRIDGE, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical...

WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) — Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced two presentations at the Jefferies Next Generation IBD Therapeutics Virtual Summit. Members of the Morphic management team are scheduled to participate in a panel discussion at 8:45 a.m. ET on Wednesday, September 23, 2020, as well as present a company overview at 1:00 p.m. ET on the same day.A live webcast of the company presentation will be available on the Investor section of Morphic’s website at https://www.morphictx.com. An archived replay will be available on the company’s website following the conference.About Morphic TherapeuticMorphic Therapeutic is a biopharmaceutical company developing...

Étude clinique de Phase 3 TRYbeCA-1 dans le traitement en seconde ligne du cancer du pancréas :Plus de 90% des patients recrutés sur un total prévu d’env. 500 patientsObtention de la désignation Fast Track de la FDA américaineAnalyse intermédiaire d’efficacité et analyse finale respectivement attendues au 1ertrimestre 2021 et au S2 2021Étude NOPHO de phase 2 IST dans le traitement en seconde ligne de la leucémie aiguë lymphoblastique :Finalisation du recrutement des patients avec 55 patients inscritsRésultats intermédiaires encourageants : niveau cible et durée de l’activité de l’asparaginase atteintsDonnées finales attendues d’ici la fin de l’année 2020Trésorerie et équivalents de trésorerie de 45,4 millions d’euros (51 millions de dollars) au 30 juin 2020Extension de l’horizon de trésorerie avec un financement par obligations...